Laboratory compliance with the american society of clinical oncology/college of american pathologists human epidermal growth factor receptor 2 testing guidelines: A 3-year comparison of validation procedures

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 7, 2014, Pages 876-884

  Dyhdalo, Kathryn S ^a   Fitzgibbons, Patrick L ^b   Goldsmith, Jeffery D ^c   Souers, Rhona J ^d   Nakhleh, Raouf E ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ST JUDE MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Molecular Pathology Division   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

BREAST TUMOR; COMPARATIVE STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; LABORATORY; MEDICAL SOCIETY; METABOLISM; PATHOLOGY; PRACTICE GUIDELINE; REVIEW; STANDARD; UNITED STATES; VALIDATION STUDY;

BREAST NEOPLASMS; DATA COLLECTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LABORATORIES; PATHOLOGY, CLINICAL; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84904011591     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0731-CP     Document Type: Review

References (16)

1. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291(16):1972-1977.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.
3. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-69.
4. Wolff A, Hammond ME, Schwartz J, et al, American Society of Clinical Oncology, College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145.
5. Nakhleh R, Grimm E, Idowu M, Souers R, Fitzgibbons P. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: A College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med. 2010;134(5):728-734.
6. Wolff A, Hammond E, Hicks D, et al; American Society of Clinical Oncology, College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-256.
7. Tong LC, Nelson N, Tsourigiannis J, Mulligan AM. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: A prospective study. Am J Surg Pathol. 2011;35(4):545-552.
8. Hammond MEH, Hayes D, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907-922.
9. Hayes D, Picard M. Heart of darkness: The downside of trastuzumab. J Clin Oncol. 2006;24(25):4056-4058.
10. College of American Pathologists. 2011 Anatomic Pathology Checklist. Northfield, IL: College of American Pathologists; 2011.
11. College of American Pathologists. 2013 Anatomic Pathology Checklist. Northfield, IL: College of American Pathologists; 2013.
12. Cell Markers and Cytogenetics Committees, College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: Quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med. 2002;126(7):803-808.
13. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19(10):2714-2721.
14. Vincent-Salomon A, MacGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: Results of the French multicentre GEFPICS study. Histopathology. 2003;42(4):337-347.
15. Ridolfi R, Jamehdor M, Arber J. HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13(8):866-873.
16. Fitzgibbons P, Murphy D, Hammond M, Allred D, Valenstein P. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med. 2010;134(6):930-935.